NASDAQ · RXRX
Healthcare · Biotechnology
$3.74
Down-$0.15 (-3.86%)
Updated Sep 26, 2026, 5:04 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RXRX closed at $3.74 after 20 trading sessions, up 11.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $3.89 | $3.90 | $3.70 | $3.74 | 10.48M |
| Sep 24, 2026 | $3.65 | $3.90 | $3.61 | $3.89 | 19.34M |
| Sep 23, 2026 | $4.03 | $4.09 | $3.66 | $3.70 | 23.67M |
| Sep 22, 2026 | $4.00 | $4.16 | $3.90 | $4.05 | 40.46M |
| Sep 21, 2026 | $3.92 | $4.015 | $3.83 | $3.97 | 37.73M |
| Sep 18, 2026 | $3.54 | $3.83 | $3.50 | $3.83 | 44.33M |
| Sep 17, 2026 | $3.28 | $3.59 | $3.26 | $3.54 | 28.25M |
| Sep 16, 2026 | $3.26 | $3.31 | $3.16 | $3.19 | 14.81M |
| Sep 15, 2026 | $3.37 | $3.37 | $3.22 | $3.24 | 11.88M |
| Sep 14, 2026 | $3.19 | $3.455 | $3.18 | $3.41 | 17.1M |
| Sep 11, 2026 | $3.21 | $3.25 | $3.15 | $3.20 | 8.03M |
| Sep 10, 2026 | $3.14 | $3.25 | $3.10 | $3.16 | 10.63M |
| Sep 9, 2026 | $3.42 | $3.45 | $3.21 | $3.215 | 14.2M |
| Sep 8, 2026 | $3.58 | $3.59 | $3.43 | $3.44 | 14.99M |
| Sep 4, 2026 | $3.415 | $3.70 | $3.41 | $3.63 | 29.04M |
| Sep 3, 2026 | $3.435 | $3.45 | $3.2901 | $3.44 | 13.75M |
| Sep 2, 2026 | $3.34 | $3.4891 | $3.285 | $3.38 | 14.05M |
| Sep 1, 2026 | $3.34 | $3.38 | $3.2801 | $3.33 | 10M |
| Aug 31, 2026 | $3.305 | $3.41 | $3.25 | $3.40 | 13.91M |
| Aug 28, 2026 | $3.40 | $3.45 | $3.31 | $3.34 | 10.56M |
The latest Smart Investors Daily articles mentioning RXRX.
RXRX research
Company profile and research snapshot.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| May 7, 2026 | Needham | Buy | — |
| Apr 30, 2026 | JP Morgan | Overweight | — |
| Feb 26, 2026 | Needham | Buy | — |
| Feb 26, 2026 | B of A Securities | Neutral | — |
No generated briefing is available yet.
Benzinga · Sep 21, 2026
Tempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
Yahoo · Sep 19, 2026
Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...
Benzinga · Sep 17, 2026
Recursion Pharmaceuticals (NASDAQ:RXRX) reported second-quarter financial results on Wednesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by
Yahoo · Sep 16, 2026
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RXRX.
